Literature DB >> 19777240

What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Xiangning Fan1, Janet Pope, Murray Baron.   

Abstract

We studied the relationships between physician-assessed damage, severity and activity in a large, multicentre systemic sclerosis (SSc, scleroderma) cohort. We hypothesized that there is a relationship between disease activity and severity and damage, but that severity would be more strongly related to damage. A total of 520 SSc patients (87% women, mean age 56 years, mean 8.6 years disease duration, 39% diffuse SSc) were studied. The correlations between physician's global assessments of damage, activity and severity were determined overall and in a subset of early, diffuse SSc (n = 74). The mean (SD) patient global health score was 3.6 (2.4) on a 0-10 scale. Physician-rated severity, activity and damage were 2.8 (2.2), 2.3 (2.0), and 3.4 (2.4) respectively. Damage was more strongly related to severity (r = 0.744, P < 0.001) than activity (r = 0.596, P < 0.001). Damage was not related to disease duration (r = 0.046, P = 0.3). In early diffuse SSc, the correlations were: damage and severity 0.771 (P < 0.001), damage and activity 0.596 (P < 0.001), severity and activity 0.809 (P < 0.001). The relationships vary in the overall cohort versus the early diffuse SSc subset where activity, severity and damage appear more strongly related. Thus, the exact nature of the relationship between damage, activity and severity will depend upon the characteristics of the population studied.

Entities:  

Mesh:

Year:  2009        PMID: 19777240     DOI: 10.1007/s00296-009-1129-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Disease severity as a predictor of outcome in scleroderma.

Authors:  Allan C Gelber; Fredrick M Wigley
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

2.  Scleroderma: health services utilization from patients' perspective.

Authors:  Sindhu R Johnson; Simon Carette; James V Dunne
Journal:  J Rheumatol       Date:  2006-06       Impact factor: 4.666

Review 3.  Disease assessment indices: activity, damage and severity.

Authors:  D P Symmons
Journal:  Baillieres Clin Rheumatol       Date:  1995-05

4.  A disease severity scale for systemic sclerosis: development and testing.

Authors:  T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.

Authors:  Philip J Clements; James R Seibold; Daniel E Furst; Maureen Mayes; Barbara White; Fredrick Wigley; Michael D Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Weng Kee Wong
Journal:  Semin Arthritis Rheum       Date:  2004-02       Impact factor: 5.532

7.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

8.  European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria.

Authors:  G Valentini; W Bencivelli; S Bombardieri; S D'Angelo; A Della Rossa; A J Silman; C M Black; L Czirjak; H Nielsen; P G Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 9.  Scleroderma--clinical and pathological advances.

Authors:  Christopher P Denton; Carol M Black
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-06       Impact factor: 4.098

10.  Localized scleroderma severity index and global assessments: a pilot study of outcome instruments.

Authors:  Thaschawee Arkachaisri; Sally Pino
Journal:  J Rheumatol       Date:  2008-03-01       Impact factor: 4.666

View more
  5 in total

1.  The challenges and controversies of measuring disease activity in systemic sclerosis.

Authors:  Laura Ross; Murray Baron; Mandana Nikpour
Journal:  J Scleroderma Relat Disord       Date:  2018-03-27

2.  The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

3.  The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

4.  Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme.

Authors:  Kathleen Morrisroe; Wendy Stevens; Joanne Sahhar; Candice Rabusa; Mandana Nikpour; Susanna Proudman
Journal:  Arthritis Res Ther       Date:  2017-03-07       Impact factor: 5.156

5.  Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients.

Authors:  Diána Simon; Péter Balogh; Szabina Erdő-Bonyár; Katalin Böröcz; Tünde Minier; László Czirják; Tímea Berki
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.